Events
Microphysiological Systems (MPS) World Summit 2025
June 9–13, 2025 | Brussels, Belgium
Join us at Booth #123 during MPS World Summit 2025 in Brussels, where LifeNet Health LifeSciences will be showcasing our full range of human-based solutions for MPS-based research. Whether you're developing new chip platforms or optimizing NAM-based studies, an MPS is only as good as the cells that go into it. That’s why LifeNet Health LifeSciences provides high-quality, human-relevant components—including hepatocytes, liver non-parenchymal cells (NPCs), and 3D thyroid microtissues—empowering researchers to build microphysiological systems with greater confidence, physiological accuracy, and data consistency.
Podium Presentation:
Don’t miss our expert-led session on, “Evaluating the kinetics, metabolism and cytotoxicity of drugs and chemicals in an integrated multi-organ MPS model”, during presentation session ‘3.4 Pharma and Toxicokinetics’ on Thursday, June 12th, starting at 1 pm CEST.
Key Takeaways:
Integrated Multi-Organ MPS Model: An advanced MPS system connecting intestine, liver, and kidney via flow was used to simulate in vivo-like pharmacokinetics and toxicity.
Comprehensive Assessment: The model evaluated absorption, metabolism, distribution, and cytotoxicity for DGA, diclofenac, and cinnamaldehyde across all organ chambers.
Predictive IVIVE Potential: Results aligned with published data, supporting the utility of this MPS approach for in vitro-to-in vivo extrapolation (IVIVE).
Presented By: Jamin Willoughby
Date: Thursday, June 12th, 2025
Time: 1:00PM – 1:20 pm CEST
Location: Tour & Taxis – Shed 2 BIS
Abstract # 596
The 21st Annual Congress of International Drug Discovery Science and Technology (IDDST)
June 18-20, 2025 | Stockholm, Sweden
LifeNet Health LifeSciences is pleased to participate in the 21st Annual Congress of International Drug Discovery Science & Technology in Stockholm, Sweden. Join us at Booth #4 to learn how we are uniquely positioned to support drug discovery at every stage — from target validation to safety assessment and translational research. Our portfolio of ethically sourced, comprehensively characterized human cells and tissues helps scientists generate more predictive, human-relevant data, ultimately accelerating the development of safer and more effective therapies.
Oral Presentation:
Join us for an oral presentation on, “Cryopreserved Primary Human Thyrocytes: A Platform for Thyroid Disease Research and Therapeutic Development”, being presented by Eda Rogers, PhD, Senior Scientist, on Friday, June 20th from 8:55 – 9:15 am CEST.
Key Learnings:
- A novel primary human thyrocyte model replicates thyroid function in 2D and 3D cultures.
- The model effectively replicated thyroid disease responses and enabled quantitative assessment of TSHR activators and inhibitors, including standard anti-thyroid drugs (MMI, PTU).
How this model supports thyroid drug discovery while reducing reliance on animal models
Session: IDDST 07: Novel Biotherapies, Natural Products & Traditional Medicine
Location: Room C5, Second Floor, Clarion Hotel Stockholm